151 related articles for article (PubMed ID: 36916768)
1. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
[TBL] [Abstract][Full Text] [Related]
2. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
5. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Weiss AR; Lyden ER; Anderson JR; Hawkins DS; Spunt SL; Walterhouse DO; Wolden SL; Parham DM; Rodeberg DA; Kao SC; Womer RB
J Clin Oncol; 2013 Sep; 31(26):3226-32. PubMed ID: 23940218
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
[TBL] [Abstract][Full Text] [Related]
7. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
10. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
[TBL] [Abstract][Full Text] [Related]
11. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
Ben-Arush M; Minard-Colin V; Scarzello G; Fajardo RD; Terwisscha Van Scheltinga S; Bernier V; Jenney M; Gallego S; Zanetti I; Cesen M; Merks JHM; Bisogno G
Eur J Cancer; 2022 Sep; 172():119-129. PubMed ID: 35763871
[TBL] [Abstract][Full Text] [Related]
12. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Gupta AA; Chi YY; Anderson JR; Lyden E; Weigel B; Arndt C; Meyer WH; Rosenberg A; Hawkins DS
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28333415
[TBL] [Abstract][Full Text] [Related]
13. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
Raney B; Anderson J; Breneman J; Donaldson SS; Huh W; Maurer H; Michalski J; Qualman S; Ullrich F; Wharam M; Meyer W;
Pediatr Blood Cancer; 2008 Jul; 51(1):17-22. PubMed ID: 18266224
[TBL] [Abstract][Full Text] [Related]
14. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
[TBL] [Abstract][Full Text] [Related]
15. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
17. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
[TBL] [Abstract][Full Text] [Related]
18. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group.
Metts J; Xue W; Gao Z; Ermoian R; Bradley JA; Arnold MA; Dasgupta R; Venkatramani R; Walterhouse D
Cancer; 2023 Jun; 129(11):1735-1743. PubMed ID: 36857314
[TBL] [Abstract][Full Text] [Related]
20. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
